Can a new vaccine stop strep a in its tracks?
NCT ID NCT07085702
First seen Aug 11, 2026 · Last updated Aug 12, 2026 · Updated 1 time
Summary
This first-in-human trial tests a new vaccine designed to protect against Group A Streptococcus (Strep A), a bacteria that can cause sore throats, skin infections, and more serious illnesses. Healthy adults aged 18 to 25 will receive one of two vaccine formulations, each with a different adjuvant (alum or AS37), at low, medium, or high doses. The study aims to see if the vaccine is safe, causes any immediate reactions, and triggers an immune response.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- A 4-component vaccine against Group A Streptococcus (Strep A), formulated with either alum or AS37 adjuvant, given in low, medium, or high doses.
- What this could lead to
- If successful, this could lead to a vaccine that prevents Strep A infections, potentially reducing serious complications like rheumatic heart disease.
- What could go wrong
- This is an early-phase trial, so the vaccine may not be safe or effective in humans. Side effects like pain, fever, or fatigue are possible.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for STREPTOCOCCAL INFECTIONS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
GSK Investigational Site
RECRUITINGBotany, New South Wales, 2019, Australia
-
GSK Investigational Site
RECRUITINGCamberwell, Victoria, 3124, Australia
More trials for these conditions
Other studies related to the condition(s) this trial covers.